Ongoing immune or infectious injury keeps inflammatory signaling active at the conjunctival surface. This environment stimulates fibroblasts, which produce and organize excess extracellular matrix. As matrix accumulates, the conjunctiva contracts and loses normal flexibility, creating adhesions and progressively changing the relationship between the eyelids and the ocular surface. The process therefore converts repeated injury into structural damage.
Fibroblasts are central effector cells in the scarring response because they generate extracellular-matrix components after persistent injury. Excessive matrix deposition thickens and contracts affected tissue rather than allowing normal surface recovery. This remodeling contributes to conjunctival shrinkage and adhesions, including symblepharon, and helps explain why controlling the initiating inflammatory or infectious stimulus is important.
Autoimmune disease and severe infection can begin with different causes, but both may sustain conjunctival inflammation long enough to activate the same scarring pathway. Persistent injury promotes fibroblast activity and matrix deposition, while the resulting anatomical changes disturb the tear film and may damage the cornea. Identifying the trigger remains important because the initiating process is not interchangeable.
Evaluation should focus on determining the underlying cause, particularly whether the condition is associated with autoimmune disease, severe infection, medication exposure, or trauma. This etiologic information supports timely diagnosis and treatment rather than addressing surface scarring alone. Recognizing the source of ongoing injury may help limit progression toward adhesions, severe dry eye, corneal injury, and vision loss.
Progressive conjunctival contraction can produce symblepharon, an adhesion between conjunctival surfaces, and can alter normal eyelid–ocular surface anatomy. Inflammation and anatomical distortion may also disrupt the tear film, causing severe dry eye, while the cornea becomes vulnerable to injury. Monitoring these outcomes is important because structural surface damage can threaten vision even after the original trigger is less active.
The condition links cause, immune or infectious injury, tissue repair, and long-term anatomical change within one ocular-surface process. Immunology research can examine how persistent inflammatory activity leads to fibroblast stimulation and matrix deposition, while infection-focused work can consider severe infection as a potential initiating insult. This connection makes the disorder relevant to both disease recognition and prevention of vision-threatening outcomes.